A review of agents in late-stage development as of March 2008 for the treatment of diabetic retinopathy, dry eye syndrome, macular degeneration, and diabetic macular edema
Is Arkansas’ New PBM Law the Right Path Forward for Reform? No One Knows Yet
May 9th 2025It could improve access to community pharmacies and lower prices. Or it will limit access to critical drugs and impact payers’ ability to contract for a broad range of services. Industry leaders are unsure about the impact of Arkansas’ law banning PBMs from owning pharmacies.
Read More